Highlights
The combination of GLP-1 receptor agonists and SGLT-2 inhibitors reduces the risk of major adverse liver outcomes by 39% compared to GLP-1 receptor agonists alone and by 43% compared to SGLT-2 inhibitors alone. Additionally, the combination therapy lowers the risk of major adverse cardiovascular events by 35% and 20%, respectively.
